hydroxychloroquine has been researched along with Myasthenia Gravis in 7 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Myasthenia Gravis: A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine treatment appears to be safe in this setting." | 6.48 | The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature. ( Amoura, Z; Benveniste, O; Cacoub, P; Chapelon, C; Costedoat-Chalumeau, N; De Gennes, C; Eymard, B; Haroche, J; Jallouli, M; Le Thi Huong, D; Leroux, G; Piette, JC; Saadoun, D; Wechsler, B, 2012) |
| "Hydroxychloroquine treatment appears to be safe in this setting." | 2.48 | The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature. ( Amoura, Z; Benveniste, O; Cacoub, P; Chapelon, C; Costedoat-Chalumeau, N; De Gennes, C; Eymard, B; Haroche, J; Jallouli, M; Le Thi Huong, D; Leroux, G; Piette, JC; Saadoun, D; Wechsler, B, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Guidon, AC | 1 |
| Amato, AA | 1 |
| Rein, N | 1 |
| Haham, N | 1 |
| Orenbuch-Harroch, E | 1 |
| Romain, M | 1 |
| Argov, Z | 1 |
| Vaknin-Dembinsky, A | 1 |
| Gotkine, M | 1 |
| Koc, G | 1 |
| Odabasi, Z | 1 |
| Tan, E | 1 |
| Fernandez-Sanz, A | 1 |
| Bucar-Barjud, M | 1 |
| Ruiz-Serrano, J | 1 |
| Saez-Comet, L | 1 |
| Capablo-Liesa, JL | 1 |
| Varan, O | 1 |
| Kucuk, H | 1 |
| Tufan, A | 1 |
| Jallouli, M | 1 |
| Saadoun, D | 1 |
| Eymard, B | 1 |
| Leroux, G | 1 |
| Haroche, J | 1 |
| Le Thi Huong, D | 1 |
| De Gennes, C | 1 |
| Chapelon, C | 1 |
| Benveniste, O | 1 |
| Wechsler, B | 1 |
| Cacoub, P | 1 |
| Amoura, Z | 1 |
| Piette, JC | 1 |
| Costedoat-Chalumeau, N | 1 |
| Muirden, KD | 1 |
3 reviews available for hydroxychloroquine and Myasthenia Gravis
| Article | Year |
|---|---|
COVID-19 and neuromuscular disorders.
Topics: Antiviral Agents; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Vaccines; Delivery of Heal | 2020 |
The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Magn | 2012 |
The use of chloroquine and D-penicillamine in the treatment of rheumatoid arthritis.
Topics: Anti-Glomerular Basement Membrane Disease; Arthritis, Rheumatoid; Captopril; Chloroquine; Clinical T | 1986 |
1 trial available for hydroxychloroquine and Myasthenia Gravis
| Article | Year |
|---|---|
The use of chloroquine and D-penicillamine in the treatment of rheumatoid arthritis.
Topics: Anti-Glomerular Basement Membrane Disease; Arthritis, Rheumatoid; Captopril; Chloroquine; Clinical T | 1986 |
4 other studies available for hydroxychloroquine and Myasthenia Gravis
| Article | Year |
|---|---|
Description of 3 patients with myasthenia gravis and COVID-19.
Topics: Adult; Aged; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatmen | 2020 |
Myasthenic Syndrome Caused by Hydroxychloroquine Used for COVID-19 Prophylaxis.
Topics: Antimalarials; Betacoronavirus; Cholinesterase Inhibitors; Coronavirus Infections; COVID-19; COVID-1 | 2020 |
[Association between myasthenia gravis and systemic lupus erythematosus: is it safe to use hydroxychloroquine?]
Topics: Adult; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Myasthenia Gravis; Retrosp | 2017 |
Myasthenia gravis due to hydroxychloroquine.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Myas | 2015 |